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1. INTRODUCTION {#cas13893-sec-0001}
===============

5‐Fluorouracil (5‐FU) is a key drug in the treatment of colon and gastric cancers. Various combination therapies have been developed and improved survival. However, survival duration remains short, and cure with chemotherapy is rarely expected.[1](#cas13893-bib-0001){ref-type="ref"}, [2](#cas13893-bib-0002){ref-type="ref"}, [3](#cas13893-bib-0003){ref-type="ref"}, [4](#cas13893-bib-0004){ref-type="ref"}, [5](#cas13893-bib-0005){ref-type="ref"} To circumvent such problems, new therapeutic strategies are needed.

In human cancers, the tumor protein (*TP*)*53* tumor suppressor gene is often inactivated by missense mutation, or its function is suppressed by enhanced expression of oncogenes such as murine double minute 2 (*MDM2*) and *MDM4*.[6](#cas13893-bib-0006){ref-type="ref"}, [7](#cas13893-bib-0007){ref-type="ref"}, [8](#cas13893-bib-0008){ref-type="ref"} MDM2 and its complex with MDM4 destabilizes p53 through binding and ubiquitin‐dependent protein degradation.[9](#cas13893-bib-0009){ref-type="ref"}, [10](#cas13893-bib-0010){ref-type="ref"} MDM4 can also repress p53 transcriptional activity by directly binding to the transactivating domain.[11](#cas13893-bib-0011){ref-type="ref"}, [12](#cas13893-bib-0012){ref-type="ref"}

Studies have shown that reactivation of wild‐type (wt) *TP53* by inhibiting MDM2‐p53 interaction or knockdown of *MDM2* and *MDM4* induces cell cycle arrest and apoptotic cell death, inhibiting tumor growth in tumors carrying wt*TP53*.[6](#cas13893-bib-0006){ref-type="ref"}, [13](#cas13893-bib-0013){ref-type="ref"}, [14](#cas13893-bib-0014){ref-type="ref"}, [15](#cas13893-bib-0015){ref-type="ref"}, [16](#cas13893-bib-0016){ref-type="ref"}, [17](#cas13893-bib-0017){ref-type="ref"}, [18](#cas13893-bib-0018){ref-type="ref"}, [19](#cas13893-bib-0019){ref-type="ref"} Thus, *MDM2* and *MDM4* are ideal targets for cancer therapy in such tumors. Various kinds of small molecular compounds and peptides inhibiting MDM2 function have been developed.[6](#cas13893-bib-0006){ref-type="ref"}, [18](#cas13893-bib-0018){ref-type="ref"}, [20](#cas13893-bib-0020){ref-type="ref"}, [21](#cas13893-bib-0021){ref-type="ref"} Among them, idasanutlin has been shown to be an effective treatment in some clinical studies of patients with malignant lymphomas and acute myeloblastic leukemias.[22](#cas13893-bib-0022){ref-type="ref"}, [23](#cas13893-bib-0023){ref-type="ref"}, [24](#cas13893-bib-0024){ref-type="ref"}

A previous study reported that cultured tumor cells with wt*TP53* can be divided into 2 types: high MDM2 expressers and high MDM4 expressers.[16](#cas13893-bib-0016){ref-type="ref"} The former expresses a high level of MDM2 and a very low level of MDM4, whereas the latter expresses a high level of MDM4 and an intermediate level of MDM2. Knockdown of either *MDM4* or *MDM2* alone using synthetic siRNAs with DNA‐substituted seed arms (chiMDM4, chiMDM2) specifically suppressed the growth of high MDM4 expresser cancer cells, whereas only *MDM2* knockdown but not *MDM4* knockdown suppressed that of high MDM2 expresser cancer cells. Simultaneous knockdown of *MDM4* and *MDM2* synergistically inhibited the growth of high MDM4 expresser cancer cells.

Overexpression or amplification of *MDM4* has been found in 19%‐49% and 43% of colon and gastric cancers, respectively, whereas those of *MDM2* have been reported in 17.3% and 32.7%‐41.8% of colon and gastric cancers, respectively.[25](#cas13893-bib-0025){ref-type="ref"}, [26](#cas13893-bib-0026){ref-type="ref"}, [27](#cas13893-bib-0027){ref-type="ref"}, [28](#cas13893-bib-0028){ref-type="ref"}, [29](#cas13893-bib-0029){ref-type="ref"} Therefore, reactivation of wt*TP53* by chiMDM4 and chiMDM2 could be used for the treatment of these cancers. In the present study, the effects of double knockdown of *MDM4* and *MDM2* using chiMDM4 and chiMDM2 on the antitumor activity of 5‐FU in colon and gastric cancer cells with wt*TP53* and high MDM4 (wt*TP53*/highMDM4) were investigated. In vivo antitumor activity of chiMDM4 plus chiMDM2 (chiMDM4/chiMDM2) and a combination of chiMDM4/chiMDM2 with 5‐FU were also explored.

2. MATERIALS AND METHODS {#cas13893-sec-0002}
========================

2.1. Cell culture {#cas13893-sec-0003}
-----------------

Four tumor cell lines with wt*TP53* were used: HCT116 colon cancer, LoVo colon cancer, SNU‐1 gastric cancer, and NUGC‐4 gastric cancer. The HCT116 cell line was purchased from Horizon Discovery (Cambridge, UK). LoVo and SNU‐1 cell lines were purchased from ATCC (Rockville, MD, USA). The NUGC‐4 cell line was obtained from the Riken BioResource Center Cell Bank (Tsukuba, Japan). HCT116, SNU‐1, and NUGC‐4 cells were cultured in RPMI‐1640 medium (Sigma‐Aldrich, St. Louis, MO, USA) supplemented with 10% FBS (Nichirei Biosciences, Tokyo, Japan). LoVo cells were cultured in Ham\'s F‐12 nutrient mixture medium (Sigma‐Aldrich) with 10% FBS. 5‐Fluorouracil was purchased from Kyowa Hakko Kirin (Tokyo, Japan). Nutlin‐3 was purchased from Calbiochem (San Diego, CA, USA).

2.2. Small interfering RNAs and transfection {#cas13893-sec-0004}
--------------------------------------------

Sequences of DNA‐modified siRNAs used in this study were: chimera Control (chiControl, chiCtrl) sense strand, 5′‐GUACCGCACGUCAttcgtatc‐3′; chiCtrl antisense strand, 5′‐tacgaaUGACGUGCGGUACGU‐3′; chiMDM2 sense strand, 5′‐CAGCCAUCAACUUctagtagc‐3′; chiMDM2 antisense strand, 5′‐tactagAAGUUGAUGGCUGAG‐3′; chiMDM4 sense strand, 5′‐CCCUCUCUAUGAUatgctaag‐3′; chiMDM4 antisense strand, 5′‐tagcatAUCAUAGAGAGGGCU‐3′; chiCtrl (in vivo) sense strand, 5′‐gtaGUACCGCACGUCAttctc‐3′; and chiCtrl (in vivo) antisense strand, 5′‐gaaUGACGUGCGGUACtacGU‐3′ (capital letters, ribonucleotides; small letters, deoxynucleotides). The control DNA‐modified siRNA was designed to have the least homology to human and mouse genes. For the in vitro experiments, DNA‐modified siRNAs were synthesized, cartridge‐purified, and annealed (Sigma‐Aldrich). For the in vivo experiments, DNA‐modified siRNAs were synthesized, annealed, and purified using HPLC (ST Pharm., Seoul, Korea). The siRNA transfection in vitro experiment was carried out using Lipofectamine RNAiMAX reagent (Invitrogen, Carlsbad, CA, USA) as reported previously,[30](#cas13893-bib-0030){ref-type="ref"} except for SNU‐1 cells. Because Lipofectamine RNAiMAX was toxic to SNU‐1 cells, the cells were exposed to siRNA‐Lipofectamine RNAiMAX complex for 4 hours, then centrifuged, resuspended in a complete medium, and cultivated. The siRNA transfection in vivo experiment was undertaken using AteloGene Local Use (Koken, Tokyo, Japan).

2.3. Cell viability {#cas13893-sec-0005}
-------------------

Water‐soluble tetrazolium salt (WST‐8) colorimetric assays were carried out using a CCK‐8 (Dojin Laboratories, Kumamoto, Japan) according to the manufacturer\'s protocol. Because the maximum knockdown effects of siRNAs were usually observed 2‐3 days after transfection, cells were incubated for 5 days after transfection with siRNAs (4 days after treatment with 5‐FU), which was longer than the period described in the manufacturer\'s protocol (1‐3 days), then analyzed using an iMark microplate reader (Bio‐Rad, Hercules, CA, USA). The absorbance of the plates was read at wavelengths of 450 and 620 nm.

2.4. Combination index {#cas13893-sec-0006}
----------------------

Quantification of the mixture of chiMDM4/chiMDM2 and 5‐FU synergy was determined by the Chou‐Talalay method for drug combination using CalcuSyn software (Biosoft, Cambridge, UK).[31](#cas13893-bib-0031){ref-type="ref"}

2.5. Immunoblot analysis {#cas13893-sec-0007}
------------------------

Both SDS‐PAGE and immunoblot analysis were carried out as previously described.[16](#cas13893-bib-0016){ref-type="ref"} The primary and secondary Abs used in this study were: mouse mAb against MDM2 (2A10) (Abcam, Cambridge, UK); goat polyclonal Ab against MDMX (D‐19) (Santa Cruz Biotechnology, Dallas, TX, USA); anti‐TP53 mouse mAb (BP53‐12) (Cell Sciences, Canton, MA, USA); mouse mAbs against p21Wafl/Cip1 (DCS60), and rabbit polyclonal Ab against p53 upregulated modulator of apoptosis (PUMA) (Cell Signaling Technology, Danvers, MA, USA); and rabbit polyclonal Ab against β‐actin (Medical & Biological Laboratories, Nagoya, Japan). Both HRP‐conjugated sheep anti‐mouse IgG and donkey anti‐rabbit IgG sera were purchased from GE Healthcare (Chicago, IL, USA). The HRP‐conjugated rabbit anti‐goat IgG was purchased from Sigma‐Aldrich. Chemiluminescent detection was carried out using ECL Select Western Blotting Detection Reagent (GE Healthcare) and the Ez‐Capture Imaging System (Atto, Tokyo, Japan).

2.6. Quantitative RT‐PCR {#cas13893-sec-0008}
------------------------

RNA samples were extracted from cell lysate using 40 μL RealTime Ready Cell Lysis reagent (Roche Diagnostics, Mannheim, Germany) per well of a 96‐well culture plate, according to the manufacturer\'s instructions. Complementary DNA was synthesized using 2 μL RNA and 8 μL Transcriptor Universal cDNA Master (Roche Diagnostics) in 20‐μL reactions. Quantitative RT‐PCR assays were carried out using the Applied Biosystems 7500 Fast Real‐Time PCR system (Applied Biosystems, Foster City, CA, USA) in 96‐well plates. Primer and TaqMan probe for CDKN1A (p21Cip1) and ACTB (β‐actin) were obtained from Applied Biosystems (Assay ID: Hs00355782_m1 and Hs99999903_m1, respectively). Reactions were carried out in triplicate under standard thermocycling conditions in a 20 μL volume containing 5 μL cDNA, 900 nmol/L primers, 250 nmol/L probe, and 10 μL TaqMan Gene Expression Master Mix (Applied Biosystems), according to the manufacturer\'s protocol. The amount of target mRNA was examined and normalized to that of β‐actin.

2.7. Cell cycle assay {#cas13893-sec-0009}
---------------------

Cells were seeded into 60‐mm dishes at 1 × 10^5^/dish. After overnight cultivation, cells were transfected with DNA‐modified siRNAs (0.5‐2 nmol/L) for 24 hours, then cultured in the presence of 5‐FU (4 μmol/L). After 2 days of cultivation, cells were gently lifted with Accutase (US Biotechnologies, Parker Ford, PA, USA) at room temperature for 10 minutes. The cells were then washed once with PBS and stained with a Cycletest Plus DNA reagent kit (BD Biosciences, Franklin Lakes, NJ, USA), according to the manufacturer\'s protocol. Flow cytometry was carried out using a FACSCalibur flow cytometer and CellQuest software (both BD Biosciences). The percentage of cells in different cell cycle phases was calculated using ModFit LT software (Verity Software House, Topsham, ME, USA).

2.8. In vivo antitumor effect of 5‐FU plus knockdown of *MDM4* and *MDM2* {#cas13893-sec-0010}
-------------------------------------------------------------------------

All animal experiments were undertaken according to procedures approved by the Institutional Animal Care and Use Committee of the University of Tsukuba (Tsukuba, Japan). Female BALB/c nude mice (5 weeks old) were obtained from Charles River Japan (Kanagawa, Japan) and maintained under specific pathogen‐free conditions in a temperature and humidity‐controlled environment. HCT116 cells were suspended in saline solution (Otsuka Pharmaceutical, Tokyo, Japan) at a concentration of 5 × 10^4^/μL. One hundred microliters of the adjusted cell suspension of HCT116 was s.c. injected into the right flank of mice under anesthesia. Ten days after inoculation, the s.c. xenografted tumors grew to approximately 50 mm^3^ in size. The mice were randomly assigned to 4 groups (n = 5 per group) as follows: chiCtrl alone (1 mg/kg), mixture of chiMDM4 and chiMDM2 (0.5 mg/kg, each), chiCtrl (1 mg/kg) plus 5‐FU (30 mg/kg), and a mixture of chiMDM4 and chiMDM2 (0.5 mg/kg, each) plus 5‐FU (30 mg/kg). DNA‐modified siRNA was directly injected into tumor once a week (days 0, 7, and 14) using AteloGene as described in the manufacturer\'s instruction. 5‐FU was i.p. injected 3 times a week for 3 weeks (days 1, 4, 6, 8, 11, 13, 15, 18, and 20). Tumor volume was measured with a caliper 3 times a week and calculated using a formula of *V *= (length × width^2^)/2. To monitor health, the mice were weighed 3 times a week, and their general physical status was recorded daily. Experiments were terminated before the largest size of tumor reached 2000 mm^3^.

2.9. Statistical analysis {#cas13893-sec-0011}
-------------------------

Statistical significance of differences between various groups was evaluated using Dunnett\'s or Tukey\'s test (in vitro assay). A repeated‐measures ANOVA was used to evaluate the in vivo antitumor effects of the drugs. A difference between the experimental groups was considered statistically significant at a *P*‐value of \<.05. All statistical analyses were undertaken using SPSS version 25.0 (SPSS, Chicago, IL, USA).

3. RESULTS {#cas13893-sec-0012}
==========

3.1. Cell growth inhibition of *MDM4*/*MDM2* double knockdown and 5‐FU in wt *TP53* colon and gastric cancer cells {#cas13893-sec-0013}
------------------------------------------------------------------------------------------------------------------

To test if double knockdown of *MDM4* and *MDM2* could enhance the antitumor activity of 5‐FU in colon and gastric cancers with wt*TP53*/high*MDM4*, the effect of chiMDM4/chiMDM2 on the growth inhibitory activity of 5‐FU was examined by WST‐8 assay using 2 colon cancer (HCT116 and LoVo) and 2 gastric cancer (SNU‐1 and NUGC‐4) cell lines. As shown in Figure [1](#cas13893-fig-0001){ref-type="fig"}A, a mixture of chiMDM4 and chiMDM2 in equimolar amounts and 5‐FU alone suppressed the growth of HCT116 cells in a dose‐dependent manner as compared with control DNA‐modified siRNA (chiCtrl). Combination of chiMDM4/chiMDM2 and 5‐FU suppressed the growth more than each alone. Similar enhancement of 5‐FU‐mediated growth suppression by chiMDM4/chiMDM2 was observed in LoVo (Figure [1](#cas13893-fig-0001){ref-type="fig"}B), SNU‐1 (Figure [1](#cas13893-fig-0001){ref-type="fig"}C), and NUGC‐4 cells (Figure [1](#cas13893-fig-0001){ref-type="fig"}D).

![Effects of double knockdown of *MDM4* and *MDM2* and 5‐fluorouracil (5‐FU) on the growth of colon (HCT116 and LoVo) and gastric cancer cell lines (SNU‐1 and NUGC‐4) with wt*TP53*/high *MDM4*. HCT116 (A), LoVo (B), SNU‐1 (C), and NUGC‐4 cells (D) were transfected with either DNA‐modified control siRNA (chiCtrl) or mixture of DNA‐modified siRNA targeting *MDM4* (chiMDM4) and *MDM2* (chiMDM2). After 4‐16 hours of incubation, cells were exposed to 5‐FU at the indicated concentrations. Five days after transfection, cell viability was determined using the WST‐8 assay. Cell viability relative to those transfected with chiCtrl are shown (mean ± SD; n = 3) . \**P* \< .05, compared with the chiCtrl](CAS-110-639-g001){#cas13893-fig-0001}

Combination index (CI) values were calculated, and they are summarized in Table [1](#cas13893-tbl-0001){ref-type="table"}. The CI value of HCT116 cells was lowest (\<0.3), followed by NUGC‐4 cells (0.83, 0.77), LoVo cells (0.90, 0.97), and SNU‐1 cells (0.95, 0.97), showing that *MDM4*/*MDM2* double knockdown enhanced the antitumor activity of 5‐FU synergistically in HCT116 cells and NUGC‐4 cells and additively in SNU‐1 cells and LoVo cells.

###### 

Combination index of mixture of chiMDM4/chiMDM2 and 5‐fluorouracil (5‐FU)

  Cell line   chiMDM4 (nmol/L)   chiMDM2 (nmol/L)   5‐FU (4 μmol/L)   Combination index
  ----------- ------------------ ------------------ ----------------- -------------------
  HCT116      0.250              0.250              \+                0.28
  0.500       0.500              \+                 0.29              
  LoVo        0.500              0.500              \+                0.90
  1.000       1.000              \+                 0.97              
  SNU‐1       0.125              0.125              \+                0.95
  0.250       0.250              \+                 0.97              
  NUGC‐4      0.500              0.500              \+                0.83
  1.000       1.000              \+                 0.77              

John Wiley & Sons, Ltd

We tested whether nutlin‐3, an inhibitor of MDM2‐p53 interaction, could serve as a substitute for chiMDM2 to enhance the antitumor effect of chiMDM4 in 4 cell lines (NUGC‐4, SNU‐1, HCT116, and LoVo). As shown in Figure [2](#cas13893-fig-0002){ref-type="fig"}A and Table [2](#cas13893-tbl-0002){ref-type="table"}, a synergistic antitumor effect of chiMDM4 and nutlin‐3 was observed in 3 cell lines (NUGC‐4, HCT116, and LoVo), whereas a mostly additive effect was seen in the SNU‐1 cell line. Next, we examined whether the combination of chiMDM4/nutlin‐3 could enhance the antitumor effect of 5‐FU in HCT116 and NUGC‐4 cells (Figure [2](#cas13893-fig-0002){ref-type="fig"}B, Table [3](#cas13893-tbl-0003){ref-type="table"}). We found that chiMDM4/nutlin3 synergistically enhanced the 5‐FU effect in HCT116 (CI, 0.55‐0.93), whereas its effect was additive or even antagonistic to 5‐FU in NUGC‐4 (CI, 0.82‐1.42).

![Effects of *MDM4* knockdown and nutlin‐3 on tumor cell growth and antitumor activity of 5‐fluorouracil (5‐FU) in colon and gastric cancer cells. A, Growth inhibitory effect of *MDM4* knockdown and nutlin‐3 in HCT116 (a), LoVo (b), SNU‐1 (c), and NUGC‐4 cells (d). Cells were transfected with either control siRNA (chiCtrl) or DNA‐modified siRNA targeting *MDM4* (chiMDM4). After 4‐16 hours of incubation, cells were exposed to nutlin‐3 at the indicated concentrations. Five days after transfection, cell viability was determined using the WST‐8 assay. Cell viability relative to those transfected with chiCtrl are shown (mean ± SD; n = 3). B, Enhancement of *MDM4* knockdown/nutlin‐3 on antitumor activity of 5‐FU in colon (HCT116) and gastric cancer cells (NUGC‐4). HCT116 (left) and NUGC‐4 cells (right) were transfected with either chiCtrl or chiMDM4. After 16 hours of incubation, cells were exposed to nutlin‐3 and 5‐FU at the indicated concentrations. Five days after transfection, cell viability was determined using the WST‐8 assay. Cell viability relative to those transfected with chiCtrl are shown (mean ± SD; n = 3)](CAS-110-639-g002){#cas13893-fig-0002}

###### 

Combination index of chiMDM4 and nutlin‐3

  Cell line   Nutlin‐3 (μmol/L)   chiMDM4 (nmol/L)   Combination index
  ----------- ------------------- ------------------ -------------------
  HCT116      1.00                0.50               0.49
  2.00        0.50                0.31               
  5.00        0.50                0.49               
  1.00        1.00                0.88               
  2.00        1.00                0.72               
  5.00        1.00                0.97               
  LoVo        1.00                1.00               0.48
  2.00        1.00                0.35               
  5.00        1.00                0.30               
  1.00        2.00                0.51               
  2.00        2.00                0.33               
  5.00        2.00                0.28               
  SNU‐1       1.00                0.25               0.96
  2.00        0.25                0.82               
  5.00        0.25                0.94               
  1.00        0.50                0.98               
  2.00        0.50                1.04               
  5.00        0.50                1.07               
  NUGC‐4      1.00                1.00               0.47
  2.00        1.00                0.23               
  5.00        1.00                0.26               
  1.00        2.00                0.54               
  2.00        2.00                0.53               
  5.00        2.00                0.68               

John Wiley & Sons, Ltd

###### 

Combination index of chiMDM4/nutlin‐3 and 5‐fluorouracil (5‐FU)

  Cell line   chiMDM4 (nmol/L)   Nutlin‐3 (μmol/L)   5‐FU (4 μmol/L)   Combination index
  ----------- ------------------ ------------------- ----------------- -------------------
  HCT116      0.5                2.0                 \+                0.55
  0.5         5.0                \+                  0.93              
  1.0         2.0                \+                  0.48              
  1.0         5.0                \+                  0.66              
  NUGC‐4      1.0                2.0                 \+                0.82
  1.0         5.0                \+                  1.06              
  2.0         2.0                \+                  1.19              
  2.0         5.0                \+                  1.42              

John Wiley & Sons, Ltd

3.2. Expression of MDM2, MDM4, p53, and their downstream molecules by *MDM4/MDM2* double knockdown {#cas13893-sec-0014}
--------------------------------------------------------------------------------------------------

To explore the mechanisms by which chiMDM4/chiMDM2 enhanced 5‐FU‐mediated growth suppression in colon and gastric cancer cells, expression changes of MDM2, MDM4*,* p53, p21, and PUMA were examined in 2 colon cancer (HCT116 and LoVo) and 2 gastric cancer cells (SNU‐1 and NUGC‐4) by immunoblotting (Figure [3](#cas13893-fig-0003){ref-type="fig"}). The results of quantification of immunoblotting bands are shown in Table [S1](#cas13893-sup-0001){ref-type="supplementary-material"}.

![Effects of double knockdown of *MDM2* and *MDM4* and 5‐fluorouracil (5‐FU) on levels of p53, p21, and p53 upregulated modulator of apoptosis (PUMA) in colon (HCT116 and LoVo) and gastric cancer cells (SNU‐1 and NUGC‐4). HCT116, LoVo, SNU‐1, and NUGC‐4 cells were transfected with either control siRNA (chiCtrl) or a mixture of DNA‐modified siRNA targeting *MDM4* (chiMDM4) and *MDM2* (chiMDM2). After 4‐16 hours of incubation, cells were exposed to 5‐FU at the indicated concentrations. Twenty‐four hours after exposure to 5‐FU, cells were analyzed for levels of MDM2, MDM4, p53, p21, and PUMA using immunoblotting. β‐actin was used as an internal control](CAS-110-639-g003){#cas13893-fig-0003}

HCT116 cells are known to have wild and mutant alleles of *MDM4*. The mutant allele contained 1 base deletion of the third nucleotide of codon 279 and resulted in frameshift and premature termination. This gave rise to a smaller protein of 289 amino acids,[32](#cas13893-bib-0032){ref-type="ref"} which retained a p53‐binding region and could exert an inhibitory effect toward p53. chiControl‐transfected HCT116 cells expressed two bands of 80 and 40 kDa (Figure [4](#cas13893-fig-0004){ref-type="fig"}), representing wild and mutant MDM4, respectively.

![Expression level of MDM4 in wt*TP53* colon (HCT116 and LoVo) and gastric cancer cell lines (SNU‐1 and NUGC‐4). Expression levels of MDM4 were analyzed by immunoblotting](CAS-110-639-g004){#cas13893-fig-0004}

chiMDM4/chiMDM2 suppressed both wild and mutant MDM4 in HCT116 and NUGC‐4 cells by 11‐ and 10‐fold, respectively, which was more efficient than in LoVo (3.8‐fold) and SNU‐1 cells (1.8‐fold). chiMDM4/chiMDM2 also decreased the levels of MDM2 in all cell lines by 1.3 to 3.7‐fold. Knockdown of *MDM4*/*MDM2* concomitantly induced the accumulation of p53 and its downstream gene products of p21 and PUMA. The enhancing effects on p53 expression were almost equivalent among the 4 cell lines (2.2 to 3.0‐fold).

5‐FU increased p53 and its responsive gene products, MDM2, p21, and PUMA to various degrees in cell lines tested here. 5‐FU accumulated MDM2 more in NUGC‐4 (8.8‐fold) and HCT116 cells (4.2‐fold) than in LoVo (3.3‐fold) and SNU‐1 cells (1.4‐fold). In contrast, the level of MDM4 was inversely related to that of MDM2, suggesting that MDM4 might be destabilized by induced MDM2 in these cells.

Treatment with chiMDM4/chiMDM2 plus 5‐FU accumulated a lower level of MDM2 than 5‐FU alone. Furthermore, chiMDM4/chiMDM2 plus 5‐FU most potently suppressed the level of MDM4 than either alone in all tested cell lines. As a result, induction of p53 and p21 was highest in these cells treated with chiMDM4/chiMDM2 plus 5‐FU compared with cells treated with either alone.

Although both MDM2 and p21 were products of p53‐responsive genes, 5‐FU increased the p21 level less than the MDM2 level in HCT116 and LoVo cells. Therefore, we analyzed *p21* mRNA levels in HCT116 cells treated with chiMDM4/chiMDM2, 5‐FU alone, and chiMDM4/chiMDM2 plus 5‐FU using quantitative RT‐PCR (Figure [5](#cas13893-fig-0005){ref-type="fig"}). Compared with *p21* mRNA levels in chiCtrl‐treated cells, 5‐FU alone, chiMDM4/chiMDM2 alone, and chiMDM4/chiMDM2 plus 5‐FU increased the level of *p21* mRNA by 2.4‐, 4.1‐, and 5.1‐fold, respectively. These results suggested that p53 activity was highest in cells treated with chiMDM4/chiMDM2 plus 5‐FU, and p21 might be destabilized by increased MDM2 in cells treated with 5‐FU.

![Effects of double knockdown of *MDM4* and *MDM2* and 5‐fluorouracil (5‐FU) on the level of *p21* mRNA in HCT116 cells. HCT116 cells were transfected with either control siRNA (chiCtrl) or a mixture of DNA‐modified siRNA targeting *MDM4* (chiMDM4) and *MDM2* (chiMDM2) for 16 hours and then cultured in the presence of 5‐FU. Forty‐eight hours after transfection, the cells were analyzed for their *p21* mRNA level using quantitative RT‐PCR. *p21* mRNA levels relative to those transfected with chiCtrl are shown. \**P* \< .05, compared with the chiCtrl](CAS-110-639-g005){#cas13893-fig-0005}

3.3. Cell cycle distribution and apoptosis {#cas13893-sec-0015}
------------------------------------------

Effects of chiMDM4/chiMDM2, 5‐FU alone, and chiMDM4/chiMDM2 plus 5‐FU on the cell cycle distribution and apoptosis of colon cancer and gastric cancer cells were examined by flow cytometry (Figure [6](#cas13893-fig-0006){ref-type="fig"}).

![Effects of double knockdown of *MDM4* and *MDM2* and 5‐fluorouracil (5‐FU) on cell cycle distribution of colon (HCT116 and LoVo) and gastric cancer cells (SNU‐1 and NUGC‐4). HCT116 (top left), LoVo (top right), SNU‐1 (bottom left), and NUGC‐4 cells (bottom right) were transfected with control siRNA (chiCtrl) or a mixture of DNA‐modified siRNA targeting *MDM4* (chiMDM4) and *MDM2* (chiMDM2) overnight, then exposed to 5‐FU. After overnight cultivation, the cells were analyzed for cell cycle distribution by flow cytometry](CAS-110-639-g006){#cas13893-fig-0006}

In HCT116 cells, chiMDM4/chiMDM2 increased the fraction of the G~1~ phase and decreased that of the S phase, showing that *MDM4*/*MDM2* double knockdown caused G~1~ arrest. 5‐FU decreased the G~1~ phase fraction and increased the S phase fraction, showing that 5‐FU caused early S phase arrest. The combination of these enhanced chiMDM4/chiMDM2‐induced G~1~ arrest, as well as apoptotic cell death detected as sub‐G~1~ fraction.

In SNU‐1 cells and LoVo cells, chiMDM4/chiMDM2 caused G~1~ arrest. 5‐FU alone caused weak G~1~ arrest in LoVo cells but had an undetectable effect on the cell cycle distribution in SNU‐1 cells. Simultaneous treatment with chiMDM4/chiMDM2 and 5‐FU alone enhanced G~1~ arrest. chiMDM4/chiMDM2 plus 5‐FU increased the population of apoptotic cells in SNU‐1 cells but not in LoVo cells.

In NUGC‐4 cells, 5‐FU alone as well as chiMDM4/chiMDM2 induced G~1~ arrest but not apoptosis. 5‐FU and chiMDM4/chiMDM2 decreased the S phase fraction, whereas a combination of these two had a faint change in the S phase fraction. Furthermore, a small increase in the G~1~ phase fraction was observed with a combination of 5‐FU and chiMDM2/chiMDM4 (5‐FU alone, 77%; chiMDM2/chiMDM4 alone, 76%; 5‐FU plus chiMDM4/chiMDM2, 80%), suggesting that chiMDM4/chiMDM2 marginally enhanced 5‐FU‐induced G~1~ arrest.

3.4. In vivo antitumor activity {#cas13893-sec-0016}
-------------------------------

To test whether chiMDM4/chiMDM2 could inhibit in vivo tumor growth and enhance the antitumor activity of 5‐FU, we examined the effects of chiCtrl, chiCtrl plus 5‐FU, chiMDM4/chiMDM2, and chiMDM4/chiMDM2 plus 5‐FU on the growth of HCT116 xenograft tumors in mice. chiMDM4/chiMDM2 alone and chiCtrl plus 5‐FU slowed the tumor growth rate compared with chiCtrl alone (Figure [7](#cas13893-fig-0007){ref-type="fig"}), showing that double knockdown suppressed in vivo tumor growth of wt*TP53*/highMDM4 colon cancer. 5‐FU plus chiMDM4/chiMDM2 most potently inhibited the tumor growth compared with chiCtrl/5‐FU and chiMDM4/chiMDM2.

![In vivo antitumor activity of a mixture of DNA‐modified siRNA targeting *MDM4* (chiMDM4) and *MDM2* (chiMDM2), 5‐fluorouracil (5‐FU), and combinations of these two in a xenograft model of HCT116 colon cancer cells. Results are expressed as means ± SE. \**P *\<* *.05, \*\**P *\<* *.001, compared with the control group (those injected with control siRNA \[chiCtrl\])](CAS-110-639-g007){#cas13893-fig-0007}

4. DISCUSSION {#cas13893-sec-0017}
=============

5‐FU is widely used for chemotherapy in various cancers including colon, stomach, and breast cancer. In our previous study, simultaneous knockdown of *MDM4* and *MDM2* using synthetic DNA‐substituted siRNAs (chiMDM4 and chiMDM2) was shown to synergistically suppress the growth of cancer cells with wt*TP53*/highMDM4.[16](#cas13893-bib-0016){ref-type="ref"} In this study, we showed that double knockdown of *MDM4* and *MDM2* enhanced the antitumor activity of 5‐FU in colon and gastric cancer cells with wt*TP53*/highMDM4.

In all cell lines used in this study, 5‐FU induces p53 expression and concomitant MDM2. Accumulated MDM2, functioning as a negative feedback regulator, can compromise p53‐mediated antitumor activity in 5‐FU‐treated cancer cells. In HCT116 cells, 5‐FU increased *p21* mRNA and MDM2 but failed to accumulate p21, suggesting that MDM2 might antagonize p53‐mediated growth inhibition through ubiquitination and destabilization of p21.[33](#cas13893-bib-0033){ref-type="ref"} In this context, *MDM2* knockdown using chiMDM4/chiMDM2 might disrupt these negative effects of MDM2 on p53‐ and p21‐mediated growth inhibition and potentiate the antitumor activity of 5‐FU.

We revealed that chiMDM4‐mediated growth inhibition could be synergistically enhanced by nutlin‐3, as was observed by chiMDM2.[34](#cas13893-bib-0034){ref-type="ref"} However, enhancement of 5‐FU antitumor activity by chiMDM4/nutlin‐3 was less efficient than that by chiMDM4/chiMDM2. Particularly in NUGC‐4 cells, chiMDM4/nutlin‐3 was even antagonistic to 5‐FU at high concentrations. 5‐FU caused MDM2 accumulation in NUGC‐4 more intensely than in HCT116 cells. Addition of nutlin‐3 to 5‐FU‐exposed cells may further the increase MDM2 level, which partially inactivates negative growth signals by direct interactions with p53, p21, RB, and E2F1 in these cells.[33](#cas13893-bib-0033){ref-type="ref"}, [35](#cas13893-bib-0035){ref-type="ref"} Small molecules and peptides targeting MDM2 and MDM4 have been developed,[18](#cas13893-bib-0018){ref-type="ref"} most of which disrupt MDM2‐p53 interactions and increase MDM2 expression, similar to nutlin‐3.[13](#cas13893-bib-0013){ref-type="ref"}, [36](#cas13893-bib-0036){ref-type="ref"} Thus, *MDM2* knockdown might have some advantages over MDM2‐p53 inhibitors in the treatment of cancers carrying wt*TP53*.

The magnitude of enhancement of chiMDM4/chiMDM2 on 5‐FU‐mediated antitumor activity appears to be related to the magnitude of MDM4 suppression. 5‐FU suppresses MDM4 in synergistic responders (HCT116 and NUGC‐4) more strongly than in additive responders (SNU‐1 and LoVo). It remains unknown how 5‐FU decreases MDM4 levels in these cells. 5‐FU might destabilize MDM4 through the increase of MDM2 induced by p53 activation because MDM2 can ubiquitinate and destabilize MDM4.[37](#cas13893-bib-0037){ref-type="ref"} Furthermore, *MDM4* knockdown by chiMDM4/chMDM2 is more efficient in synergistic responders (HCT116 and NUGC‐4) than additive responders (LoVo and SNU‐1). The expression level of MDM4 differs among cell lines (Figure [4](#cas13893-fig-0004){ref-type="fig"}). Synergistic responders (HCT116 and NUGC‐4) express higher levels of MDM4 than additive responders (SNU‐1 and LoVo). Synergistic responders could be more dependent on MDM4 expression for their growth and survival than additive responders.[38](#cas13893-bib-0038){ref-type="ref"}, [39](#cas13893-bib-0039){ref-type="ref"} Knockdown efficiency of synthetic siRNA might depend on various factors, including transfection efficiencies of siRNA and RNA‐induced silencing complex formation. RNA‐induced silencing complex formation could be determined by the abundance of AGO2 protein, Hsc70/Hsp90 chaperone, and endoribonuclease complex, consisting of Trax and Translin.[40](#cas13893-bib-0040){ref-type="ref"} Factors regulating *MDM4* knockdown efficiency are now being analyzed.

This study shows that 5‐FU causes similar p53 accumulation in all colon and gastric cancer cell lines carrying wt*TP53*/highMDM4. However, the effect of 5‐FU on the cell cycle distribution differs among them: 5‐FU causes cell cycle arrest in the early S phase in HCT116 cells, whereas it induces G~1~ arrest in LoVo cells and NUGC‐4 cells. 5‐FU has two independent mechanisms of action.[41](#cas13893-bib-0041){ref-type="ref"}, [42](#cas13893-bib-0042){ref-type="ref"}, [43](#cas13893-bib-0043){ref-type="ref"} It blocks DNA replication by inhibiting thymidine synthesis, resulting in cell cycle arrest in the early S phase. It also causes nucleolar stress by being incorporated into ribosomal RNA and interfering in subsequent ribosomal RNA processing. This leads to p53 activation, which induces G~1~ arrest and apoptosis. 5‐FU might activate p53 more potently in LoVo and NUGC‐4 cells than in HCT116 cells. Although inhibition of DNA replication has been reported as the major mechanism of action of 5‐FU in most cancer cells, the magnitude of nucleolar stress could vary among cell lines, dependent on the efficiency of fluorouridine incorporation into ribosomal RNA. Although 5‐FU causes early S‐phase arrest in HCT116 cells, its combination with chiMDM4/chiMDM2 dramatically shifts the effect on cell cycle distribution from early S‐phase arrest to G~1~ arrest with strong p53 activation. This result suggests that the addition of chiMDM4/chiMDM2 might change the main action mechanism of 5‐FU from inhibition of DNA replication to augmented activation of p53.

chiMDM4/chiMDM2 plus 5‐FU induced larger populations of apoptotic cells in SNU‐1 cells than in LoVo cells. Activated p53 can trigger apoptosis by modulating the expression of genes involved in intrinsic (eg, *PUMA*,*BAX*, and *BCL2*) and extrinsic apoptosis pathways (FAS‐L and FAS).[44](#cas13893-bib-0044){ref-type="ref"} Inducibility of p53‐mediated apoptosis depends on the expression and structures of these genes in individual cell lines. LoVo cells but not SNU‐1 cells carry *BAX* mutations,[45](#cas13893-bib-0045){ref-type="ref"}, [46](#cas13893-bib-0046){ref-type="ref"} which could be one of the mechanisms by which some cancer cells acquire resistance to p53‐triggered apoptosis.

In the present study, we show that *MDM4*/*MDM2* double knockdown inhibits in vivo tumor growth and enhances the antitumor effect of 5‐FU without any intolerable toxicity. Recent advances in the delivery system for oligonucleotides[47](#cas13893-bib-0047){ref-type="ref"} could enable chiMDM4/chiMDM2 to be applied to the treatment of wt*TP53*/highMDM4 tumors. Approximately 50% of human cancers express wt*TP53*,[48](#cas13893-bib-0048){ref-type="ref"} in some fraction of which wt*TP53* is directly suppressed by MDM2 alone or MDM2 combined with MDM4. Thus, MDM2 and MDM4 are ideal targets of therapy for these tumors. In addition, *MDM2* knockout was shown to suppress the growth of tumors lacking *TP53* alleles by inducing p53‐responsive gene through *TP73*‐mediated transactivation.[49](#cas13893-bib-0049){ref-type="ref"} *MDM4*/*MDM2* knockdown can be potentially used for the treatment of cancers lacking p53 expression.

In conclusion, the double knockdown of *MDM4* and *MDM2* enhances in vitro and in vivo antitumor activity of 5‐FU toward gastrointestinal cancer with wt*TP53*/highMDM4. Combination of siRNAs targeting *MDM4* and *MDM2* and cytotoxic anticancer drugs including 5‐FU could be a novel therapeutic strategy for such cancers.
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